6-Methyl-MDA

6-Methyl-MDA

Systematic (IUPAC) name
1-(6-methyl-1,3-benzodioxol-5-yl)propan-2-amine
Clinical data
Routes of administration	Oral
Legal status	Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar bills in other countries)
Identifiers
ATC code	none
PubChem	CID 10511982
ChemSpider	8687383
ChEMBL	CHEMBL6376
Chemical data
Formula	C11NO2
Molar mass	193.24 g/mol
SMILES O1c2cc(c(cc2OC1)CC(N)C)C
InChI InChI=1S/C11H15NO2/c1-7-3-10-11(14-6-13-10)5-9(7)4-8(2)12/h3,5,8H,4,6,12H2,1-2H3 Key:HCFHWXDIZOAUTQ-UHFFFAOYSA-N
(verify)

6-Methyl-3,4-methylenedioxyamphetamine (6-Methyl-MDA) is an entactogen and psychedelic drug of the amphetamine class.^[1] It was first synthesized in the late 1990s by a team including David E. Nichols at Purdue University while investigating derivatives of MDA and MDMA.^[1]

6-Methyl-MDA has IC₅₀ values of 783nM, 28,300nM, and 4,602nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine in rat synaptosomes.^[1] In animal studies it substitutes for MBDB, MMAI, LSD, and DOI, though not amphetamine, but only partially and at high doses.^[1] Thus, while several-fold less potent than its analogues 2-methyl-MDA and 5-methyl-MDA, and approximately half as potent as MDA, 6-methyl-MDA is still significantly active,^[1] and appropriate doses may be similar to or somewhat higher than those of MDMA.

See also

• 2-Methyl-MDA
• 5-Methyl-MDA
• MMDA-2
• MADAM-6

References

1. Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE (March 1998). "Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry 41 (6): 1001–5. doi:10.1021/jm9705925. PMID 9526575.